Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| A Foundation Building Strength | OTHER |
Not provided
Not provided
Not provided
The goal of this study is to establish a research network to help define the natural disease history and clinical outcome measures for Nemaline Myopathy (NM).
The long-term aim of this study is to incorporate these outcome measures into clinical trials for NM therapies. Outcome measures to be assessed will be dependent on the participant's age and functional status. Follow-up visits will be conducted either every 3 or 6 months, dependent on age, for a total of 3 years.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Individuals with Nemaline Myopathy | All participants in the study will have a diagnosis of Nemaline Myopathy, with either a pathogenic or likely pathogenic mutation in ACTA1 (AD) or NEB (AR). Participants can be either ambulatory or non-ambulatory and must be between the ages of 0-18. |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Validate the change over 36 months using the Alberta Infant Motor Scale (AIMS) Score | The AIMS is a standardized tool used to assess a child's gross motor development in four positions: prone, supine, sitting, and standing. Percentile scores are given from 0-100, with higher percentiles representing higher motor function. | 36 months |
| Validate the change over 36 months using the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) | The CHOP-INTEND assesses a child's ability to move their body in a lying down position, supported sitting, and assisted rolling through 16 items. | 36 months |
| Validate the change over 36 months using the Hammersmith Infant Neurological Examination Section 2 (HINE-2) | This is a 37-item measure of infant developmental motor milestones divided into the following categories: neurological examination, developmental milestones and behavioral scale, and state of consciousness. Scores for individual categories will be combined into a composite score.This will be performed in participants aged 0-24months. Scores are interpreted in relation to optimality scores and cut-off scores for the participant's age. Higher scores represented higher function. | 36 months |
| Validate the change in 32-item Motor Function Measure (MFM32) Scale Score | This motor function assessment consists of 32 items organized in three dimensions: standing position and transfers, axial and limb proximal motor function, and limb distal motor function. Total scores are given between 0-100, with 0 indicating severe functional impairment and 100 indicating no functional impairment. | 36 months |
| Change in Peabody Developmental Motor Scales (PDMS-3) Scale Score | This is used to measure various motor abilities in young children. Four types of normative scores are yielded: age equivalents, percentile ranks, subtest scaled scores, and composite index scores. Age equivalents are indexes of relative standing that translate subtest raw scores into motor ages. Percentiles provide the examiner with an index that is easily understood. Subtest scaled scores are based on a distribution having a mean of 10 and a standard deviation of 3. Composite indexes are based on a distribution with a mean of 100 and a standard deviation of 15. Higher scores indicate higher level of function. |
| Measure | Description | Time Frame |
|---|---|---|
| Change in muscle thickness of lower extremity muscles over 36 months as measured by muscle ultrasound. | This will be conducted in a subset of participants aged >5 years. | Baseline through month 36 |
| Skin Biopsy (optional) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Participants will be identified through several sources. The primary source will be through our NM-CRN MDA care center network. Participants will also be recruited through the CMDIR and the Beggs Laboratory. Information regarding the study will be disseminated to all MDA clinics through the MDA website and via email to clinic directors. In addition, the study will advertised to families through A Foundation Building Strength, which maintains a patient information website and newsletter.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Carolina Tesi-Rocha, MD | Contact | 650-723-0993 | ctesiroc@stanford.edu | |
| Sarah Ismail, BSc | Contact | 650-460-4596 | sismail@stanford.edu |
| Name | Affiliation | Role |
|---|---|---|
| Carolina Tesi-Rocha, MD | Stanford University | Principal Investigator |
| Tina Duong, PT, PhD | Stanford University | Principal Investigator |
| John W Day, MD, PhD |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Stanford University/Lucile Packard Children's Hospital | Palo Alto | California | 94304 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D017696 | Myopathies, Nemaline |
| D009468 | Neuromuscular Diseases |
| D009224 | Myotonia Congenita |
| ID | Term |
|---|---|
| D020914 | Myopathies, Structural, Congenital |
| D009135 | Muscular Diseases |
| D009140 | Musculoskeletal Diseases |
| D009422 | Nervous System Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Plasma, serum and DNA samples will be retained. Exact amounts will depend on age of participant.
| 36 months |
| Change in ambulation over 36 months as measured by the 10 meter walk (m/s). | This test measures the time taken for a participant to walk 10 metres as quickly and safely as possible. This will be performed in ambulatory participants aged 2 years and older. | 36 months |
| Change in ambulation over 36 months as measured by the 6 Minute Walk Test | This is a measure of how far a participant can walk along a track in 6 minutes. This will be performed in ambulatory participants aged 5 years and older. | 36 months |
| Change in respiratory function over 36 months as measured by spirometry, specifically the supine forced vital capacity (FVC). | This is a measure (% predicted) of the maximum amount of air that can be forcibly exhaled from your lungs after taking the deepest breath possible. This will be performed in participants aged 5 years and older. | 36 months |
This optional outcome measure involves a one-time removal of three to four 2mm pieces of skin from one body site.
| Baseline through month 36 |
| Stanford University |
| Principal Investigator |
| Leslie Hayes, MD | Boston Children's Hospital | Principal Investigator |
| Alan Beggs, PhD | Boston Children's Hospital | Principal Investigator |
| Jim Dowling, MD, PhD | The Hospital for Sick Children | Principal Investigator |
| Richard Finkel, MD | St Jude Children's Hospital | Principal Investigator |
| Carsten Bonnemann, MD, PhD | National Institutes of Health (NIH) | Principal Investigator |
| Kaitlin Batley, MD | UT Southwestern Medical Centre | Principal Investigator |
| National Institute of Health | Bethesda | Maryland | 20892 | United States |
|
| Boston Children's Hospital | Boston | Massachusetts | 02115 | United States |
|
| St Jude Children's Research Hospital | Memphis | Tennessee | 38105 | United States |
|
| UT Southwestern Medical Centre/Children's Health Dallas | Dallas | Texas | 75207 | United States |
|
| The Hospital for Sick Children | Toronto | Ontario | M5G 1E8 | Canada |
|
| D020967 | Myotonic Disorders |
| D020271 | Heredodegenerative Disorders, Nervous System |
| D019636 | Neurodegenerative Diseases |
| D030342 | Genetic Diseases, Inborn |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |